Skip to content

Study · Not a test of the peptide alone · 2017

1 result

Characterization of in vitro generated metabolites of selected peptides <2 kDa prohibited in sports.

Thomas A, Knoop A, Schänzer W, Thevis M

Drug testing and analysis13 Nov 2017Cited by 15 (Europe PMC)

PMID28941172 (opens in a new tab)DOI10.1002/dta.2306 (opens in a new tab)PepBankPUB-28941172
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cibinetide (ARA-290) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cibinetide (ARA-290).

  1. 01LabNot a test of Cibinetide (ARA-290) aloneEx vivo tissuePharmacokinetics

    In in vitro blood specimen incubations, ARA‑290 showed extensive exopeptidase-driven metabolism with one main metabolite, PyrEQLERALN.

    In plain wordsIn lab tests, ARA‑290 was broken down extensively by enzymes, mainly into one product.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    Not applicableIn vitro metabolism of ARA-290
    Study

    n: not reported in source

    EDTA-, heparin-, citrate-plasma and serum; recombinant amidase
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    extensive exopeptidase-driven metabolism was observed for ARA-290 (with one main metabolite PyrEQLERALN)
    1 context sentence
    Summary · context
    The prohibited peptides ARA-290, GHRP-3, and Peforelin, with a to-date unknown metabolism, were chosen as model compounds for these experiments and metabolism after incubation with different blood specimens (EDTA-, heparin-, citrate-plasma, and serum) and exposure to recombinant amidase were investigated.

    In this study, Cibinetide (ARA-290) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cibinetide (ARA-290).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.